HUTCHMED (China) (0013) AI Stock Analysis

• Market Cap: £22.45B
• Dividend Yield: N/A
• Average Volume (3M): 8.39M
• Price to Earnings (P/E): 6.1
• Beta (1Y): 1.07
• Revenue Growth: -1.78%
• EPS Growth: N/A
• Country: HK
• Employees: 1,811
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 4.04
• Shares Outstanding: 872,149,000
• 10 Day Avg. Volume: 3,339,108
• 30 Day Avg. Volume: 8,387,458
• PEG Ratio: -1.04
• Price to Book (P/B): 3.28
• Price to Sales (P/S): 3.96
• P/FCF Ratio: -143.13
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £29.59
• Price Target Upside: 16.51% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 58 Neutral
• Price Target: HK$27.00 ▲(6.30% Upside)

The overall stock score reflects a mixed financial performance with significant operational challenges and liquidity issues. The technical analysis indicates a lack of strong momentum, while the low P/E ratio suggests potential undervaluation. The absence of dividend yield and earnings call data limits further insights.

Positive Factors

Negative Factors

HUTCHMED (China) Business Overview & Revenue Model

Company Description

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

How the Company Makes Money

HUTCHMED makes money through a combination of product sales, collaborations, and licensing agreements. The company's revenue streams include the commercialization of its proprietary drugs, particularly in the oncology sector, where it markets and sells pharmaceuticals both independently and through strategic alliances with global pharmaceutical companies. Additionally, HUTCHMED generates income from research and development collaborations, receiving milestone payments and royalties from its partnerships. Significant partnerships with major pharmaceutical firms enhance its market reach and contribute to its revenue through joint ventures and co-development agreements.

HUTCHMED (China) Financial Statement Overview

Summary

The financial performance is mixed. Despite a significant net profit margin due to a one-time gain, revenue has declined, and operational margins are negative, indicating inefficiencies. The balance sheet is stable with low leverage, but cash flow issues persist, highlighting liquidity challenges.

Income Statement

The income statement shows a mixed performance. The TTM data indicates a significant net profit margin of 77.53%, primarily due to a one-time gain, as historical data shows much lower margins. Revenue has declined by 2.27% in the TTM, reflecting challenges in maintaining growth. Gross profit margin has decreased significantly from previous years, indicating potential cost pressures or pricing challenges. EBIT and EBITDA margins are negative, suggesting operational inefficiencies.

Balance Sheet

The balance sheet is relatively stable with a low debt-to-equity ratio of 0.076, indicating conservative leverage. The return on equity has improved significantly to 46.95% in the TTM, driven by the net income spike. However, the equity ratio has decreased over time, suggesting a need for careful capital management to maintain financial stability.

Cash Flow

Cash flow analysis reveals challenges, with negative operating cash flow in the TTM. Free cash flow has improved but remains negative, indicating liquidity issues. The operating cash flow to net income ratio is negative, highlighting a disconnect between reported earnings and cash generation. The free cash flow to net income ratio is positive, suggesting some improvement in cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	602.20M	630.20M	838.00M	426.41M	356.13M	227.98M
Gross Profit	53.76M	281.32M	151.55M	115.31M	97.89M	39.46M
EBITDA	-7.49M	14.11M	67.27M	-401.11M	-321.13M	-182.89M
Net Income	466.88M	37.73M	100.78M	-360.83M	-194.65M	-125.73M
Balance Sheet
Total Assets	1.78B	1.27B	1.28B	1.03B	1.37B	724.12M
Cash, Cash Equivalents and Short-Term Investments	1.36B	836.11M	886.34M	631.00M	1.01B	439.04M
Total Debt	93.44M	89.82M	86.13M	27.01M	34.07M	35.71M
Total Liabilities	534.02M	502.34M	536.39M	392.57M	333.15M	205.17M
Stockholders Equity	1.23B	759.93M	730.54M	610.37M	986.89M	484.12M
Cash Flow
Free Cash Flow	-49.66M	-17.44M	186.65M	-305.26M	-220.98M	-81.65M
Operating Cash Flow	-32.56M	497.00K	219.26M	-268.60M	-204.22M	-62.07M
Investing Cash Flow	-73.03M	-96.06M	-291.14M	296.59M	-306.32M	-125.44M
Financing Cash Flow	11.22M	-30.67M	48.66M	-82.76M	650.03M	296.43M

HUTCHMED (China) Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 25.40
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0013, the sentiment is Neutral. The current price of 25.4 is below the 20-day moving average (MA) of 25.94, below the 50-day MA of 25.70, and above the 200-day MA of 24.13, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 48.17 is Neutral, neither overbought nor oversold. The STOCH value of 75.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0013.

HUTCHMED (China) Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0512	73 Outperform	HK$29.78B	14.13	12.65%	3.10%	10.56%	-13.58%
0867	71 Outperform	$34.40B	19.23	10.01%	2.15%	11.78%	19.06%
3933	67 Neutral	HK$29.02B	8.09	21.02%	4.34%	0.39%	4.94%
3320	62 Neutral	€30.22B	9.94	5.90%	2.77%	―	―
0013	58 Neutral	£22.45B	6.09	48.58%	―	-1.78%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

HUTCHMED (China) Corporate Events

HUTCHMED to Present R&D Updates on October 31, 2025

HUTCHMED (China) Limited has announced a Research & Development update event scheduled for October 31, 2025, in Shanghai and via webcast. The event will feature insights from Dr. Michael Shi on the company’s R&D strategy, focusing on its Antibody Targeted Therapy Conjugates platform and lead candidate HMPL-A251, as well as updates on late-stage pipeline development. This event highlights HUTCHMED’s ongoing commitment to advancing its therapeutic offerings and maintaining its position in the biopharmaceutical industry.

The most recent analyst rating on (HK:0013) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.

HUTCHMED to Showcase New Clinical Data at Major Oncology Conferences in 2025

HUTCHMED (China) Limited announced that it will present new and updated clinical data from its studies at the 2025 World Conference on Lung Cancer and the CSCO Annual Meeting. The presentations will include data on savolitinib, a MET tyrosine kinase inhibitor developed with AstraZeneca, and HMPL-653, a CSF-1R inhibitor, among others. These presentations underscore HUTCHMED’s ongoing commitment to advancing cancer treatment and highlight its strategic collaborations and innovative pipeline, potentially enhancing its position in the oncology market.

The most recent analyst rating on (HK:0013) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.

HUTCHMED Announces Board Composition and Roles

HUTCHMED (China) Limited has announced the composition of its Board of Directors, which includes a mix of executive, non-executive, and independent non-executive directors. The company has also detailed the roles and committee memberships of each board member, highlighting the leadership structure and governance framework. This announcement provides insights into the company’s governance and strategic oversight, which could impact its operational efficiency and stakeholder confidence.

The most recent analyst rating on (HK:0013) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.

HUTCHMED Appoints Johnny Cheng as Acting CEO Amid Leadership Transition

HUTCHMED (China) Limited has announced that Dr. Weiguo Su, the company’s Chief Executive Officer, will take a leave of absence due to health reasons. In his absence, Mr. Johnny Cheng, currently the Chief Financial Officer, will assume the role of Acting Chief Executive Officer. Mr. Cheng will manage the company’s day-to-day operations while Dr. Su remains as Chief Scientific Officer, supported by the scientific team to continue the company’s drug research and discovery pipeline. The Board has expressed confidence that all research, development, and commercial initiatives will remain on track during this interim period.

The most recent analyst rating on (HK:0013) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.

HUTCHMED Completes Enrollment for Key Lung Cancer Drug Trial

HUTCHMED has completed patient enrollment for the SANOVO Phase III trial in China, testing the combination of ORPATHYS® and TAGRISSO® as a first-line treatment for certain non-small cell lung cancer patients. This trial aims to assess the efficacy and safety of the drug combination compared to TAGRISSO® alone, with results expected in the second half of 2026. Successful outcomes could lead to a new drug application in China, potentially enhancing HUTCHMED’s market position in the oncology sector.

The most recent analyst rating on (HK:0013) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.